Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1701-1704

  Zerboni, Leigh ^a   Nader, Sonia ^a   Aoki, Kristan ^a   Arvin, Ann M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; CYTOKINE; GAMMA INTERFERON; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

EID: 0031781203     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517426     Document Type: Article

References (15)

1. Arvin AM. Varicella-zoster virus. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996: 2547-85.
2. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;524-6.
3. Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis 1990;161:661-6.
4. Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis 1990;162:1049-54.
5. Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 1995; 171:13-7.
6. Arbeter AM. Clinical trials of varicella vaccine in healthy adolescents and adults. Infect Dis Clin North Am 1996;10:609-15.
7. Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988;158:132-7.
8. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991;87:604-10.
9. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990;116:184-9.
10. + T lymphocytes and epidermal cells in SCID-hu mice. J Virol 1995;69:5236-42.
11. Zhang Y, White CJ, Levin M, Hayward A. Cytokine production in varicella-zoster virus-stimulated lymphocyte cultures. Neurology 1995; S38-40.
12. Krah DL. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am 1996;10:507-26.
13. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 1985; 75:667-71.
14. Gershon AA. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis 1995;10:93-124.
15. Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 1995;172:217-9.